NXN Financials: Results, Ratios & Statements | Nexsen

NXN

Nexsen

Pharmaceuticals, Biotechnology & Life Sciences

Short position

short percentage0.02%

reported shorts21.8K

shares on issue92.766M

Nexsen (ASX:NXN) has 0.02% of its shares on issue reported as short positions as of 6 July 2026, or about 21,838 shares. NXN is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Latest result

Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency

Revenue: $1.1M (source: ASX (Markit))vs $931.6K (source: ASX (Markit)) (FY25); ASX (Markit), as at 29 Sep 2026
NPAT: −$6.6Mvs −$5.0M (source: ASX (Markit)) (FY25); Yahoo Finance, as at 29 Sep 2026
EPS (diluted): −$0.036vs −$0.025 (FY25); Yahoo Finance, as at 29 Sep 2026

Rev YoY: +16.9%FY
EPS YoY: n/aFY

ASX (Markit)

Key ratios

Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026

Gross margin: n/a
Operating margin: −630.2%
Net margin: −601.8%
FCF margin: n/a
ROE: n/a
ROA: n/a
FCF conversion: n/a
Net cash (excl. leases): $4.5M
Net debt / EBITDA: n/a
Current ratio: 4.9×
Interest cover: −8.8×
Cash dividends paid / net profit: n/a
Market cap: $28.0M
P/E: n/a
P/B: 5.0×

Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.

Financial statements

Figures in AUD, the reporting currency; Yahoo Finance unless marked

NXN income, newest period first, figures in AUD
Line item	FY26	FY25
Revenue	$1.1M (source: ASX (Markit))	$931.6K (source: ASX (Markit))
Operating income	−$6.9M	n/a
Interest expense	$780.0K	n/a
Pretax income	−$6.6M	n/a
Tax	$0	n/a
NPAT	−$6.6M	−$5.0M (source: ASX (Markit))
Net interest income	−$693.9K	n/a
EPS basic	−$0.036	−$0.025
EPS diluted	−$0.036	−$0.025
Shares	200.2M	n/a

ASX (Markit)

Financial reports

The company's own filings, newest first